Focus: Xilio Therapeutics is a pre-revenue cancer immunotherapy biotech focused on developing novel oncology treatments for advanced solid tumors. The company operates as a private, early-stage biotechnology firm headquartered in Waltham, MA.
Profile data last refreshed 17h ago · AI intelligence enriched 2w ago
No open roles listed right now. Follow Xilio Therapeutics to get notified when they start hiring — the background below is worth knowing for when they do.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Xilio Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Xilio Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
XLO Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
XLO Financials: Income Statement, Balance Sheet & Cash Flow Stock Titan
Xilio Therapeutics Announces New Preclinical Data at AACR Annual Meeting for XTX601, a Masked T Cell Engager Targeting CLDN18.2 - Sahm
Xilio Therapeutics Announces New Preclinical Data at AACR Annual Meeting for XTX601, a Masked T Cell Engager Targeting CLDN18.2 Sahm
Xilio Therapeutics (XLO) grants director 10,000 stock options at $8.40 - Stock Titan
Xilio Therapeutics (XLO) grants director 10,000 stock options at $8.40 Stock Titan
Xilio Therapeutics (XLO) director Cheryl Blanchard enters as reporting insider - Stock Titan
Xilio Therapeutics (XLO) director Cheryl Blanchard enters as reporting insider Stock Titan
Xilio Therapeutics, Inc. Files 8-K Current Report with SEC – Company and Entity Information, April 2026 - Minichart
Xilio Therapeutics, Inc. Files 8-K Current Report with SEC – Company and Entity Information, April 2026 Minichart
Xilio Therapeutics (NASDAQ: XLO) adds Cheryl Blanchard to board roles - Stock Titan
Xilio Therapeutics (NASDAQ: XLO) adds Cheryl Blanchard to board roles Stock Titan
Showing 6 of 10 news items
No open positions listed yet. Check their careers page directly.
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/moBased on last 4 crawl cycles